Animal-based radiation absorbed dose evaluation of holmium-166 labeled hydroxyapatite particulates in liver malignancies.

Q3 Medicine

Asia Oceania Journal of Nuclear Medicine and Biology Pub Date : 2025-01-01 DOI:10.22038/aojnmb.2024.79679.1560

Reza Bagheri, Hassan Ranjbar

{"title":"Animal-based radiation absorbed dose evaluation of holmium-166 labeled hydroxyapatite particulates in liver malignancies.","authors":"Reza Bagheri, Hassan Ranjbar","doi":"10.22038/aojnmb.2024.79679.1560","DOIUrl":null,"url":null,"abstract":"Objectives: Liver malignancies are among the most prevalent causes of cancer-related deaths worldwide. Intra-arterial administration of particulates labeled with beta-emitting radionuclides is one of the non-surgical promising modalities for the treatment of liver cancer.Methods: In this work, the radiation absorbed dose of 166Ho-hydroxyapatite (166Ho-HA) radiopharmaceutical was estimated for adult men based on biodistribution data in normal Wistar rats. The MIRD dose calculation method and the Sparks and Aydogan methodology were applied.Results: The results show that more than 84% of the absorbed dose is localized in liver tissue (7.35 mGy MBq-1). Also, radiation absorbed doses of 166Ho-HA for red bone marrow, osteogenic cells, and spleen tissues were estimated to be about 0.18, 0.38, and 0.24 mGy MBq-1, respectively. The maximum administrated activity was obtained at 87.5 MBq kg-1 of body weight with an effective dose of 0.39 mSv MBq-1. The maximum tolerable dose (MTD) for liver tissue was 6.13 GBq (165.56 mCi).Conclusion: This study indicated that 166Ho-HA can provide an impressive dose for liver cancer malignancies with an insignificant dose to healthy tissues.","PeriodicalId":8503,"journal":{"name":"Asia Oceania Journal of Nuclear Medicine and Biology","volume":"13 1","pages":"94-101"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11682468/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Oceania Journal of Nuclear Medicine and Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22038/aojnmb.2024.79679.1560","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Liver malignancies are among the most prevalent causes of cancer-related deaths worldwide. Intra-arterial administration of particulates labeled with beta-emitting radionuclides is one of the non-surgical promising modalities for the treatment of liver cancer.

Methods: In this work, the radiation absorbed dose of ¹⁶⁶Ho-hydroxyapatite (¹⁶⁶Ho-HA) radiopharmaceutical was estimated for adult men based on biodistribution data in normal Wistar rats. The MIRD dose calculation method and the Sparks and Aydogan methodology were applied.

Results: The results show that more than 84% of the absorbed dose is localized in liver tissue (7.35 mGy MBq^-1). Also, radiation absorbed doses of ¹⁶⁶Ho-HA for red bone marrow, osteogenic cells, and spleen tissues were estimated to be about 0.18, 0.38, and 0.24 mGy MBq^-1, respectively. The maximum administrated activity was obtained at 87.5 MBq kg^-1 of body weight with an effective dose of 0.39 mSv MBq^-1. The maximum tolerable dose (MTD) for liver tissue was 6.13 GBq (165.56 mCi).

Conclusion: This study indicated that ¹⁶⁶Ho-HA can provide an impressive dose for liver cancer malignancies with an insignificant dose to healthy tissues.

查看原文本刊更多论文

肝脏恶性肿瘤中钬-166标记羟基磷灰石颗粒的动物辐射吸收剂量评价。

目的：肝恶性肿瘤是世界范围内最常见的癌症相关死亡原因之一。动脉内给药带有β -放射核素标记的微粒是治疗肝癌的一种有希望的非手术方式。方法：根据正常Wistar大鼠的生物分布数据，估计成年男性166ho -羟基磷灰石（166Ho-HA）放射性药物的辐射吸收剂量。采用火花法和埃尔多安法计算MIRD剂量。结果：肝组织吸收剂量超过84% （7.35 mGy MBq-1）。此外，估计166Ho-HA对红骨髓、成骨细胞和脾脏组织的辐射吸收剂量分别约为0.18、0.38和0.24 mGy MBq-1。在87.5 MBq kg-1体重时获得最大给药活性，有效剂量为0.39 mSv MBq-1。肝组织最大耐受剂量（MTD）为6.13 GBq （165.56 mCi）。结论：本研究表明，166Ho-HA对肝癌恶性肿瘤具有显著的治疗作用，而对健康组织的治疗作用不显著。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊